Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

Similar articles for PubMed (Select 24130502)

1.

Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.

DeKelver RC, Lewin B, Lam K, Komeno Y, Yan M, Rundle C, Lo MC, Zhang DE.

PLoS Genet. 2013;9(10):e1003765. doi: 10.1371/journal.pgen.1003765. Epub 2013 Oct 10.

2.

A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.

Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, Zhang DE.

Nat Med. 2006 Aug;12(8):945-9. Epub 2006 Jul 30.

PMID:
16892037
3.

RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.

DeKelver RC, Lewin B, Weng S, Yan M, Biggs J, Zhang DE.

Leuk Lymphoma. 2014 Apr;55(4):884-91. doi: 10.3109/10428194.2013.815351. Epub 2013 Jul 25.

4.

RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.

Yan M, Ahn EY, Hiebert SW, Zhang DE.

Blood. 2009 Jan 22;113(4):883-6. doi: 10.1182/blood-2008-04-153742. Epub 2008 Nov 25.

5.

Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.

Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, Hoogenkamp M, Wu M, Care M, McNeill H, Cauchy P, Cullen M, Tooze RM, Tenen DG, Young BD, Cockerill PN, Westhead DR, Heidenreich O, Bonifer C.

Leukemia. 2012 Aug;26(8):1829-41. doi: 10.1038/leu.2012.49. Epub 2012 Feb 20.

6.

Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.

Ter Elst A, Ma B, Scherpen FJ, de Jonge HJ, Douwes J, Wierenga AT, Schuringa JJ, Kamps WA, de Bont ES.

Cancer Res. 2011 Apr 1;71(7):2761-71. doi: 10.1158/0008-5472.CAN-10-0402. Epub 2011 Mar 29.

7.

The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.

Bakshi R, Zaidi SK, Pande S, Hassan MQ, Young DW, Montecino M, Lian JB, van Wijnen AJ, Stein JL, Stein GS.

J Cell Sci. 2008 Dec 1;121(Pt 23):3981-90. doi: 10.1242/jcs.033431. Epub 2008 Nov 11.

8.

Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.

Kagiyama Y, Kitaura J, Togami K, Uchida T, Inoue D, Matsukawa T, Izawa K, Kawabata KC, Komeno Y, Oki T, Nakahara F, Sato K, Aburatani H, Kitamura T.

Int J Hematol. 2012 Nov;96(5):638-48. doi: 10.1007/s12185-012-1207-6. Epub 2012 Oct 25.

PMID:
23097187
9.

[Advances on pathogenesis research of acute myeloid leukemia with t(8;21)-- review].

Zeng HM, Guo Y, Zhu XF.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Dec;18(6):1632-7. Review. Chinese.

PMID:
21176386
10.

Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.

DeKelver RC, Yan M, Ahn EY, Shia WJ, Speck NA, Zhang DE.

Blood. 2013 May 2;121(18):3714-7. doi: 10.1182/blood-2012-11-465641. Epub 2013 Feb 20.

11.

Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.

Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC, Yan M, Zhang DE.

Blood. 2007 Aug 1;110(3):799-805. Epub 2007 Apr 5. Review.

12.

Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia.

Matsuura S, Yan M, Lo MC, Ahn EY, Weng S, Dangoor D, Matin M, Higashi T, Feng GS, Zhang DE.

Blood. 2012 Mar 29;119(13):3155-63. doi: 10.1182/blood-2011-04-350694. Epub 2012 Jan 5.

13.

Transcription of the AML1/ETO chimera is guided by the P2 promoter of the AML1 gene in the Kasumi-1 cell line.

Markova EN, Kantidze OL, Razin SV.

Gene. 2012 Dec 1;510(2):142-6. doi: 10.1016/j.gene.2012.09.028. Epub 2012 Sep 17.

PMID:
22995345
14.

Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.

Wichmann C, Chen L, Heinrich M, Baus D, Pfitzner E, Zörnig M, Ottmann OG, Grez M.

Cancer Res. 2007 Mar 1;67(5):2280-9.

15.

[Effective and specific control of aml1/eto gene expression in acute myeloid leukemia cells by lentivecior-based RNA-interference].

Grinev VV, Posrednik DV, Heidenreich O.

Mol Biol (Mosk). 2011 Mar-Apr;45(2):335-45. Russian.

PMID:
21634121
16.

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW.

Nat Med. 2002 Jul;8(7):743-50. Epub 2002 Jun 24.

PMID:
12091906
17.

Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.

Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, Chan KK, Perrotti D, Marcucci G.

J Pharmacol Exp Ther. 2007 Jun;321(3):953-60. Epub 2007 Mar 26.

18.

AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.

Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD.

Blood. 2000 Dec 1;96(12):3939-47.

19.

Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia.

Tonks A, Pearn L, Musson M, Gilkes A, Mills KI, Burnett AK, Darley RL.

Leukemia. 2007 Dec;21(12):2495-505. Epub 2007 Sep 27.

PMID:
17898786
20.

AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.

Dunne J, Gascoyne DM, Lister TA, Brady HJ, Heidenreich O, Young BD.

Cancer Res. 2010 May 15;70(10):3985-95. doi: 10.1158/0008-5472.CAN-09-3604. Epub 2010 May 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk